ASCO 2022 | Remaining questions regarding PSMA radioligand therapies

Andrei Gafita, MD, University of California, Los Angeles, CA, talks on remaining questions regarding PSMA radioligand therapies, including how best to select patients who will respond to treatment and deciding when patients should discontinue treatment. Dr Gafita hopes that the development of the novel framework for treatment response evaluation in PSMA-PET/CT (RECIP) will aid in these endeavors. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.